Categories: News

Acutus Medical’s Pulsed Field Ablation System To Be Featured During 27th Annual AF Symposium

CARLSBAD, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the company’s attendance at the 27th Annual AF Symposium.

Cases performed at Na Homolce Hospital in Prague, Czech Republic, by physicians Jacob Koruth, M.D., Mount Sinai Health System, Jan Petru, M.D., Na Homolce Hospital, and Vivek Reddy, M.D., Director, Cardiac Arrhythmia Service, Mount Sinai Health System, will feature the AcQMap 3D Imaging and Mapping System, the AcQBlate Force catheter*, and Acutus’ focal force sensing Pulsed Field Ablation (PFA) system**. Petr Neuzil, M.D., Ph.D., FESC, Na Homolce’s Head of Cardiology and Principal Investigator for the AcQForce PFA-CE study, will present the cases on Saturday, January 15, between 10 a.m. and 12:30 p.m. ET, highlighting the versatility of Acutus technology to map and treat a variety of arrhythmias with a single system.

Additionally, abstract poster presentations demonstrating the efficiency and efficacy of the AcQMap 3D Imaging and Mapping System, as well as the AcQCross Universal Transseptal Crossing System, will be on display. To learn more about Acutus Medical’s complete portfolio of access, diagnostic, mapping and therapy products, please visit https://acutusmedical.com.

The symposium brings together hundreds of leaders in the field of electrophysiology from across the world to educate and present the latest clinical, technological and procedural advancements for the management of atrial fibrillation (AF). To register for the 27th Annual International AF Symposium, an informative three-day scientific program, and for more information on CME, visit https://www.afsymposium.com/.

*AcQBlate Force is currently indicated for RF energy in Europe and is investigational in the U.S.
**The Acutus PFA System is under investigation in CE Mark countries.

About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

Follow Acutus Medical on: Twitter, LinkedIn, YouTube and Facebook.

US Media Contacts
Holly Windler
(619) 929-1275
holly.windler@acutus.com

Adam King
(260) 408-5383
acutus@levitatenow.com

Investor Contact
Caroline Corner
(415) 202-5678
caroline.corner@westwicke.com

Staff

Recent Posts

8-Year-Old Piano Prodigy Zeke Walters Strikes a Chord at Sinceri Senior Living Community

VANCOUVER, WA / ACCESSWIRE / March 22, 2024 / At just eight years old, Zeke…

5 mins ago

IRLAB Receives Minutes From End-of-Phase 2 Meeting Confirming Alignment with the FDA on the Phase III Program For Mesdopetam

GOTHENBURG, SWEDEN / ACCESSWIRE / March 22, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB…

5 mins ago

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or…

5 mins ago

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…

5 mins ago

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere…

5 mins ago